OA2-AM24-ST-26 - Blood donor SARS-CoV-2 Infection and Vaccination is not Associated with Adverse Outcomes in Plasma and Platelet Transfusion Recipients Without Acute COVID-19

Saturday, October 19, 2024

1:45 PM - 2:45 PM

Location: 342

CE: Zero

Presenting Author(s)

Nareg Roubinian, MD, MPHTM

Clinical Investigator
Kaiser Permanente Northern California Division of Research
Oakland, California, United States

Disclosure(s): No financial relationships to disclose

PDF

Disclosure(s):

Nareg Roubinian, MD, MPHTM: No financial relationships to disclose

Background/Case Studies: Despite data supporting the safety of SARS-CoV-2 vaccination and COVID-19 convalescent plasma, concerns persist regarding the receipt of blood products from donors previously infected or vaccinated against SARS-CoV-2. We assessed whether transfusion of plasma or platelet products from donors with prior SARS-CoV-2 infection or vaccination was associated with adverse outcomes in patients without COVID-19.

Study

Design/Methods: We linked donor SARS-CoV-2 spike and nucleocapsid antibody data and vaccination survey history to plasma or platelet units transfused to hospitalized adult patients without active SARS-CoV-2 infection between 6/1/2020 and 3/31/2022. We used logistic regression to adjust for demographics and comorbidities to calculate odds ratios and 95% confidence intervals for post-transfusion thrombosis and increased oxygen requirements. Outcomes were assessed per transfused unit from previously infected or vaccinated donors compared to units from uninfected or unvaccinated donors. As a sub-analysis, we examined whether the transfusion of the first donation following SARS-CoV-2 vaccination or infection was associated with our outcomes.

Results/Findings:

Among 8,247 hospitalizations of 7,227 plasma or platelet transfusion recipients with linked donor SARS-CoV-2 antibody data, there were 271 post-transfusion thrombotic events, and oxygen requirements were increased after transfusion in 742 hospitalizations. Among 13,429 transfused plasma units, 4,133 and 893 were from vaccinated donors and previously infected donors, respectively. Among 17,814 transfused platelet units, 7,595 and 1,129 were from vaccinated and previously infected donors, respectively. There were no associations of thrombosis or increased oxygen requirements with plasma or platelet transfusions from vaccinated or previously infected donors (Table 1). Nor were the odds of adverse outcomes increased when examining transfusion of first plasma or platelet donations following donor SARS-CoV-2 vaccination or infection.

Conclusions: Transfusion of plasma and platelet blood components from blood donors with prior SARS-CoV-2 infection or vaccination was not associated with increased adverse outcomes in transfusion recipients without COVID-19.